Literature DB >> 30118338

The nocebo effect: a clinical challenge in the era of biosimilars.

Lieven Pouillon1,2, Marie Socha3,4, Beatrice Demore4,5, Nathalie Thilly5,6, Vered Abitbol7, Silvio Danese8, Laurent Peyrin-Biroulet1.   

Abstract

INTRODUCTION: The nocebo effect is defined as a negative effect of a pharmacological or non-pharmacological medical treatment that is induced by patients' expectations, and that is unrelated to the physiological action of the treatment. The nocebo effect is an important clinical challenge in the current era of biosimilars. Areas covered: This review aims to answer five key questions about the nocebo effect, namely to reveal its definition, pathophysiology, clinical relevance, contributing factors, and management. Expert commentary: The nocebo effect lowers patients' quality of life and negatively affects treatment adherence rates in biosimilar-treated patients. It may negatively impact on the cost-savings of biosimilars. Health-care providers in charge of biosimilar-treated patients need to be aware of the nocebo effect and adopt strategies to minimize it. They have to be well-informed and confident about the existing evidence about biosimilars. A good patient-physician relationship will improve patients' acceptance of biosimilars, and limits the risk of inappropriate negative bias and the nocebo effect.

Entities:  

Keywords:  Biosimilars; biologicals; inflammatory bowel disease; nocebo effect; switching

Mesh:

Substances:

Year:  2018        PMID: 30118338     DOI: 10.1080/1744666X.2018.1512406

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  18 in total

1.  [Biosimilars and the nocebo effect].

Authors:  J Braun; S Tsiami; B Buehring; D Kiefer; I Andreica; X Baraliakos; U Kiltz
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

2.  Biosimilars for the Treatment of Inflammatory Bowel Disease.

Authors:  Vivek A Rudrapatna; Fernando Velayos
Journal:  Pract Gastroenterol       Date:  2019-04

3.  Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.

Authors:  Laurent Peyrin-Biroulet; Sanna Lönnfors; Luisa Avedano; Silvio Danese
Journal:  United European Gastroenterol J       Date:  2019-10-14       Impact factor: 4.623

4.  Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.

Authors:  Soo Kyung Cho; Sun Young Jung; Hyoungyoung Kim; Yeo Jin Song; Kyungeun Lee; Yoon Kyoung Sung
Journal:  J Korean Med Sci       Date:  2021-05-24       Impact factor: 2.153

Review 5.  The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.

Authors:  Eva Rahman Kabir; Shannon Sherwin Moreino; Mohammad Kawsar Sharif Siam
Journal:  Biomolecules       Date:  2019-08-24

Review 6.  The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.

Authors:  HoUng Kim; Rieke Alten; Luisa Avedano; Axel Dignass; Fernando Gomollón; Kay Greveson; Jonas Halfvarson; Peter M Irving; Jørgen Jahnsen; Péter L Lakatos; JongHyuk Lee; Souzi Makri; Ben Parker; Laurent Peyrin-Biroulet; Stefan Schreiber; Steven Simoens; Rene Westhovens; Silvio Danese; Ji Hoon Jeong
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

Review 7.  Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease.

Authors:  Eman Al Sulais; Turki AlAmeel
Journal:  Biologics       Date:  2020-01-10

Review 8.  The Clinical Implications of Nocebo Effects for Biosimilar Therapy.

Authors:  Luana Colloca; Remo Panaccione; T Kevin Murphy
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

Review 9.  Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?

Authors:  Roy Fleischmann; Vipul Jairath; Eduardo Mysler; Dave Nicholls; Paul Declerck
Journal:  Rheumatol Ther       Date:  2020-01-16

10.  Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients.

Authors:  Karoline Soares Garcia; Bianca Pocopetz Facas; Marta Brenner Machado; Fábio Vieira Teixeira; Luisa Avedano; Sanna Lönnfors; Rogério Saad Hossne; Laurent Peyrin-Biroulet; Natália Sousa Freitas Queiroz
Journal:  Therap Adv Gastroenterol       Date:  2021-05-18       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.